Presentations will feature clinical results for ribupatide, a GLP-1/GIP receptor dual agonist being developed as a once-weekly injection and a once-daily oral pill for the treatment of obesity and overweight Additional data from Phase 2 obesity clinical trial of ribupatide oral demonstrating mean weight loss of up to 12.1% with no observed plateau and up to 38.6% of participants achieving at least 15% weight loss at 26 weeks; incidence of gastrointestinal adverse events was low, with vomiting reported in 11.4% and 7.5% of participants taking 25 mg and 50 mg ribupatide oral, respectively Phase 1 single ascending dose trial, the first ribupatide injection clinical data generated outside of China, demonstrated similar exposure, tolerability, and weight reduction in participants of Asian and non-Asian descentSHANGHAI and WALTHAM, Mass.,...

•Translational data presented at ADA demonstrate icovamenib’s potential to promote muscle preservation and fat reduction, supporting its broader therapeutic utility in obesity and diabetes, including as a complementary therapy alongside GLP-1 receptor agonists to enhance metabolic health outcomes • Clinical data presented at ADA from COVALENT-112 show improvements in HbA1c and C-peptide in type 1 diabetes patients treated with icovamenib, with no evidence of immune activation, and inflammatory markers stable or reduced • Additionally, the Company expanded its Phase I BMF-650 study to evaluate a rapid one-step titration and enhanced weight loss potential with its oral GLP-1 receptor agonist SAN CARLOS, Calif., June 05, 2026 (GLOBE NEWSWIRE) — Biomea Fusion, Inc. (“Biomea” or the “Company”) (Nasdaq: BMEA), a clinical-stage diabetes...

MONTREAL, June 05, 2026 (GLOBE NEWSWIRE) — This press release is disseminated by Knight Therapeutics Inc. (“Knight”) (TSX:GUD), a pan-American (ex-US) pharmaceutical company, as required by Regulation 62-103 respecting the Early Warning System and Related Take-Over Bid and Insider Reporting Issues regarding securities of Crescita Therapeutics Inc. (“Crescita”).  Crescita has announced the closing of the previously announced plan of arrangement (the “Arrangement”) with ClinActiv Holdings Inc. (“ClinActiv”) and its wholly-owned subsidiary (the “Purchaser”), pursuant to which the Purchaser acquired all the issued and outstanding common shares of Crescita (the “Shares”) in exchange for a cash consideration of $0.80 per Share.  Prior to the closing of the Arrangement, Knight had control over 1,935,489 Shares representing approximately...

GUADALAJARA, Mexico, June 05, 2026 (GLOBE NEWSWIRE) — Grupo Aeroportuario del Pacífico, S.A.B. de C.V., (NYSE: PAC; BMV: GAP) (“the Company” or “GAP”) announces preliminary terminal passenger traffic figures for May 2026, compared with May 2025. During May 2026, the 12 Mexican airports operated by GAP recorded a 2.8% decrease in total passenger traffic compared to May 2025. Guadalajara airport reported an increase of 7.1%, while Puerto Vallarta, Tijuana and Los Cabos reported a decrease of 14.4%, 9.8%, and 6.0%, respectively, compared to May 2025. With respect to GAP’s airports in Jamaica, Montego Bay recorded a decrease of 19.1%, while Montego Bay recorded a decrease of 5.2%.Domestic Terminal Passengers (in thousands):             Airport May-25 May-26 % Change Jan – May 25 Jan – May 26 % ChangeGuadalajara 1,023.4 1,085.9 6.1% 5,112.0 5,187.7 1.5%Tijuana* 730.5 664.5 (9.0%) 3,536.6 3,304.7 (6.6%)Los...

TORTOLA, British Virgin Islands, June 05, 2026 (GLOBE NEWSWIRE) — Orca Energy Group Inc. (“Orca” or the “Company” and includes its subsidiaries and affiliates) (TSX-V: ORC.A, ORC.B) today announces that it has filed its condensed consolidated interim (unaudited) financial statements and management’s discussion and analysis for the three month period ended March 31, 2026 (“Q1 2026”) with the Canadian securities regulatory authorities. All amounts are in United States dollars (“$”) unless otherwise stated. HighlightsRevenue for Q1 2026 increased by $3.0 million (12%) compared to the same prior year period, primarily as a result of a higher volumes, partially offset by the increase in the Tanzanian Petroleum Development Corporation (“TPDC”) share of revenue. Additional Gas volumes increased by 7.7 MMcfd (11%) for Q1 2026 compared...

VANCOUVER, British Columbia, June 05, 2026 (GLOBE NEWSWIRE) — Blue Jay Gold Corp. (TSXV: JAY) (“Blue Jay” or the “Company”), announces two concurrent capital markets engagements: (i) the retention of Oak Hill Financial Inc. (“Oak Hill”) to provide business and capital markets advisory services including investor relations, effective June 5, 2026; and (ii) the retention of Haywood Securities Inc. (“Haywood”) to provide market-making services for the common shares of the Company, effective June 4, 2026. Oak Hill Financial Inc. – Investor Relations Advisory Oak Hill will provide business and capital markets advisory services, including raising the Company’s profile with the investment community, assisting in the development and dissemination of investor presentation materials, and delivering regular monthly progress reports. The initial...

MONTREAL, June 05, 2026 (GLOBE NEWSWIRE) — PREMIER HEALTH OF AMERICA INC. (TSX-V: PHA) (“Premier Health”, or the “Company”) announces that, further to its press release dated June 2, 2026, the Autorité des marchés financiers, as the Company’s principal regulator, has granted a management cease trade order (the “MCTO”) under National Policy 12-203 – Management Cease Trade Orders. As previously announced, the Company’s unaudited interim financial statements and the related management’s discussion and analysis for the quarter ended March 31, 2026 (the “Required Filings”) were not filed by June 1, 2026, being the filing deadline prescribed under applicable Canadian securities law requirements. The MCTO prohibits the Company’s Interim Chief Executive Officer, the Interim Chief Financial Officer and the members of the Board of Directors...

BAYONNE, N.J., June 05, 2026 (GLOBE NEWSWIRE) — BCB Bancorp, Inc. (the “Company”), (NASDAQ: BCBP), the holding company for BCB Community Bank (the “Bank”), today announced that, as previously reported on its Form 8-K filed on June 1, 2026, effective as of the close of trading on June 5, 2026, the Company granted 709,220 shares of restricted common stock, in accordance with Nasdaq Listing Rule 5635(c)(4), to Thomas M. O’Brien as an inducement material to Mr. O’Brien entering into an employment agreement with the Company and commencing employment as its Chief Executive Officer and President. Twenty percent of the shares of restricted stock will vest on each of December 31, 2026, December 31, 2027, December 31, 2028, December 31, 2029 and December 31, 2030, subject to Mr. O’Brien’s continued service with the Bank through each such...

Press release – No. 13 / 2026 New data from Phase 2 ZUPREME-1 trial at the American Diabetes Association 2026 Scientific Sessions further support potential of petrelintide to redefine the weight management experience for people living with overweight and obesityClinically meaningful, double-digit weight loss demonstrated through week 42 Placebo-like tolerability observed and low rates of treatment discontinuation due to gastrointestinal adverse events Treatment associated with improvements in cardiometabolic disease risk factors, including reductions in waist circumference, high-sensitivity C-reactive protein and triglycerides  Data reinforces the potential of petrelintide to enhance treatment persistence and address current challenges of treatment durability, tolerability and acceptability Phase 3 trials for chronic weight management...